Thumbnail Image
Publication

The dynamics of the serum concentration of CEA, CA15-3 and CA19-9 and survival in patients treated for advanced breast and colorectal cancer. The determination of the prognostic correlates of changes in tumour markers CEA, CA15-3 and CA19-9 during chemotherapy treatment for advanced breast and colorectal cancer.

Barker, Laura C.
Publication Date
2010-10-07T09:32:10Z
End of Embargo
Supervisor
Loadman, Paul
Keywords
Breast neoplasms, Colorectal neoplasms, Palliative chemotherapy, Survival, CA15-3 antigen, CA19-9 antigen, Carcinoembryonic antigen, Tumour markers, Breast cancer, Colorectal cancer
Rights
Creative Commons License
The University of Bradford theses are licenced under a Creative Commons Licence.
Peer-Reviewed
Open Access status
Accepted for publication
Institution
University of Bradford
Department
Department of Life Sciences
Awarded
2010
Embargo end date
Collections
Theses
Show all metadata
Files
Thumbnail Image
Thesis
Adobe PDF, 1.32 MB
Additional title
Abstract
There is evidence that kinetics of tumour markers (TMs) CEA, CA15-3 and CA19-9 provide valuable information about disease state over time in patients with advanced breast and colorectal cancer but the literature contains differences in methodology so comparing findings is difficult. By modifying criteria developed by Rustin and colleagues [1-5] in ovarian carcinoma we have retrospectively identified a subset of patients (those with progressive (P) TMs) where survival is significantly reduced compared with those with responsive (R) TMs. This is true for CEA, CA15-3 and CA19-9 at the first chemotherapy given in advanced disease (chem1) (Hazard ratios (HR) = 9.99, 8.89, 5.75, P ¿ 0.001 in all cases) and CEA and CA19-9 at the second chemotherapy (chem2) (HR = 7.95, 9.00, P = 0.001 and 0.002 respectively) in patients with breast cancer. It is also true for CEA at chem1 in patients with colorectal cancer (HR = 2.51, P <0.001). Further studies are necessary to see if treatment directed by these criteria can influence survival. CEA and CA19-9 Rustin category in colorectal patients and CA15-3 Rustin category in breast patients correlated significantly with radiological category at chem1 and chem2 (CEA rs = 0.45 and 0.43, CA19-9 rs = 0.26 and 0.35, CA15-3 rs = 0.28 and 0.44). CA19-9 also correlates with radiological category at chem2 (rs = 0.38) in breast patients. This provides valuable information because RECIST criteria can delay radiological identification of disease progression compared with WHO criteria [6, 7] and new therapies may act to stabilise tumour growth rather than reduce it [8].
URI
http://hdl.handle.net/10454/4443
Version
Citation
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Thesis
Qualification name
MPhil
Notes